PagerDuty, Inc. Investigation Ongoing: Contact Levi & Korsinsky to Discuss Your Rights – PD

NEW YORK, NY / ACCESS Newswire / January 8, 2026 / Levi & Korsinsky notifies investors that it has commenced an investigation of PagerDuty, Inc. ("PagerDuty, Inc.") (NYSE:PD) concerning possible violations of federal securities laws. On the evening of November 25, 2025, PagerDuty published results for the third quarter of fiscal 2026, disclosing a reduction […]

Military Metals Announces Buyback of 1% Royalty on Slovakian Portfolio

Vancouver, British Columbia–(Newsfile Corp. – January 8, 2026) – Military Metals Corp. (CSE: MILI) (OTCQB: MILIF) (FSE: QN90) (the “Company”) is pleased to announce it has exercised its buyback right to retire the 1% net smelter royalty (“NSR”) that applied to its Slovakian portfolio. The 1% NSR covered three mineral properties, including the flagship Trojarová Antimony

Perseverance Metals Intersects High Grade 4.07% Nickel over 2.1m with 0.69% Copper, 0.12% Cobalt, and 1.86g/t PGEs from Baseline Zone Discovery, Lac Gayot Project, Quebec

Vancouver, British Columbia–(Newsfile Corp. – January 8, 2026) – Perseverance Metals Inc. (TSXV: PMI) (“Perseverance“, “PMI” or the “Company“) is very pleased to provide assay results from six additional diamond drill holes (BAS-25-003 to 008), including 2.1m of massive sulphides previously announced. These holes were drilled to target Ni-Cu-Co-PGE magmatic sulphide mineralization within the Baseline Zone Discovery, part

AGM Group Announces Strategic Memorandum of Understanding with Amber Premium in Building RWA Tokenization Initiatives

(NASDAQ:AGMH), NEW YORK, Jan. 08, 2026 (GLOBE NEWSWIRE) — AGM Group Holdings Inc. (“AGM Holdings” or the “Company”) (NASDAQ: AGMH), an integrated technology company specializing in the assembling and sales of high-performance hardware and computing equipment, today announced that it has entered into a Memorandum of Understanding (“MOU”) with Amber Premium, a global leading digital

Acrivon Therapeutics Announces Positive ACR-368 Phase 2b Endometrial Cancer Clinical Data with EU Expansion to Accelerate Enrollment, Initial ACR-2316 Clinical Data, and ACR-6840, its Next AP3-Enabled Development Candidate, Targeting CDK11

(NasdaqGM:ACRV), Electronic data capture (EDC) extract from the ongoing ACR-368 registrational-intent Phase 2b monotherapy trial in OncoSignature-positive (BM+) subjects with endometrial cancer (EC) showed 39% overall response rate (ORR) and 44% in subjects with less-than or equal to2 prior lines of therapy* Analysis of data from all-comer subjects with serous subtype and less-than or equal

Alveus Therapeutics Launches with $160 Million Series A Financing to Advance Next-Generation Therapies for Obesity and Metabolic Diseases

Financing supports Phase 2 development of ALV-100, IND filing of ALV-200 and advancement of additional programs across the R&D pipeline ALV-100, a bifunctional GIPR antagonist / GLP-1R agonist, designed for durable weight management with improved quality of weight loss and long-term maintenance Differentiated amylin-based pipeline, including an AMYR3 peptide agonist (ALV-200) and oral small molecule

ZenaTech Completes 20th Acquisition in Year One of Drone as a Service, Strengthening California Wildfire Management and Public Works Opportunities

(NASDAQ:ZENA),(Boerse Frankfurt – Freiverkehr:49Q),(BMV:ZENA), VANCOUVER, British Columbia, Jan. 08, 2026 (GLOBE NEWSWIRE) — ZenaTech, Inc. (Nasdaq: ZENA) (FSE: 49Q) (BMV: ZENA) (“ZenaTech”), a technology solution provider specializing in AI (Artificial Intelligence) drone, Drone as a Service (DaaS), enterprise SaaS, and Quantum Computing solutions, today announces it has completed its 20th acquisition. The most recent acquisition

Plus Therapeutics Announces Read Out of Type B Meeting with the FDA with Goal of Accelerating Approval of REYOBIQ(TM) for Leptomeningeal Metastases

(NASDAQ:PSTV), HOUSTON, Jan. 08, 2026 (GLOBE NEWSWIRE) — Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), a healthcare company developing and commercializing precision diagnostics and radiopharmaceuticals for central nervous system (CNS) cancers, announces the completion of a Type B meeting with the U.S. Food and Drug Administration (FDA) on next steps on REYOBIQ pivotal

Electra Provides Update on Refinery Project Progress

(TSX-V:ELBM),(NASDAQ:ELBM), TORONTO, Jan. 08, 2026 (GLOBE NEWSWIRE) — Electra Battery Materials Corporation (NASDAQ: ELBM; TSX-V: ELBM) (“Electra” or the “Company”), a leader in advancing North America's critical minerals processing, is pleased to provide an update on construction progress at North America's first cobalt sulfate refinery. “Momentum continues to build across the project,” said Paolo Toscano,

Dragonfly Energy Issues Year-End CEO Letter to Shareholders

(NASDAQ:DFLI),(NASDAQ:DFLIW), RENO, Nev., Jan. 08, 2026 (GLOBE NEWSWIRE) — Dragonfly Energy Holdings Corp. (Nasdaq: DFLI) (“Dragonfly Energy” or the “Company”), an industry leader in energy storage, today issued a Year-End Letter to Shareholders from its Chief Executive Officer and President, Dr. Denis Phares. Dear DFLI Shareholders, 2025 marked an important inflection point in Dragonfly Energy's

Scroll to Top